- /
- Supported exchanges
- / US
- / KNSA.NASDAQ
Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 841 M
- EBITDA: 102 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Kiniksa Pharmaceuticals Ltd Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-07-28
- EPS/Forecast: 0.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. Continue Reading
Three Biotech Stocks Stick Out With Their Stellar Charts
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months. Continue Reading
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan. Continue Reading
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Kiniksa Pharmaceuticals International, Plc LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fi...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.